IGF-1 LR3 · Research brief

Wolverine Stack Research Bloodwork to Track — Key Markers

Real Peptides Research TeamEditorial

Updated July 10, 20269 min read

44 WORDS

Short answer

Research published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone secretagogue protocols can increase IGF-1 levels by 30–50% within 8–12 weeks. But without baseline and follow-up bloodwork, researchers have no way to verify peptide authenticity, dosing accuracy, or physiological response.

Key takeaways

IGF-1 is the primary efficacy marker for Wolverine stack protocols. An IGF-1 increase of 30–50% from baseline within 6–8 weeks confirms peptide activity and proper dosing.
Fasting glucose and HbA1c must be monitored every 6–12 weeks because growth hormone opposes insulin signalling and promotes gluconeogenesis, increasing diabetes risk in susceptible individuals.
Lipid panel changes are variable. Most researchers see triglyceride reduction and modest HDL increase, but LDL can rise; ApoB provides more precise cardiovascular risk assessment than LDL cholesterol alone.
Liver enzymes (AST/ALT) should remain stable; elevation above 1.5× the upper reference limit signals hepatic stress and requires protocol cessation.
Thyroid function testing (TSH, free T3, free T4) is often skipped but critical. Growth hormone can suppress T4-to-T3 conversion, causing low-energy symptoms despite normal TSH.
Baseline bloodwork before starting any growth hormone secretagogue protocol is non-negotiable. Without it, there's no reference point to assess whether changes are favourable, adverse, or within expected ranges.

Our team has worked with hundreds of researchers designing Wolverine stack protocols. The biggest mistake isn't dosing or timing. It's skipping the bloodwork that proves whether the peptides are working at all.

What bloodwork should you track when researching the Wolverine stack?

Researchers using the Wolverine stack. Typically combining GHRP-2, GHRP-6, or ipamorelin with a growth hormone-releasing hormone (GHRH) analogue like CJC-1295 or Modified GRF(1-29). Should track IGF-1 (insulin-like growth factor 1), comprehensive metabolic panel (CMP), lipid panel, fasting glucose, HbA1c, liver enzymes (AST/ALT), and thyroid function (TSH, free T3, free T4). Baseline bloodwork before starting the stack and follow-up testing at 6–8 weeks allows researchers to assess peptide efficacy, detect adverse metabolic shifts, and adjust dosing protocols accordingly.

Most peptide protocols are designed around dosing schedules and injection timing. That's backwards. The Wolverine stack research bloodwork to track isn't optional context. It's the primary data that determines whether the protocol is working, whether the peptides are legitimate, and whether dose adjustments are needed. This article covers which biomarkers matter most, why each one shifts under growth hormone secretagogue protocols, what reference ranges signal proper response versus adverse effects, and how to interpret results when multiple markers move simultaneously.

IGF-1 and Growth Hormone Axis Markers

IGF-1 (insulin-like growth factor 1) is the most direct biomarker for assessing growth hormone secretagogue efficacy in research settings. When GHRP-2, GHRP-6, or ipamorelin binds to ghrelin receptors in the pituitary, the resulting GH pulse triggers hepatic IGF-1 synthesis within 4–6 hours. IGF-1 has a half-life of approximately 12–15 hours, making it a stable marker for evaluating cumulative GH exposure over several days. Unlike serum GH itself, which peaks and clears within 90 minutes of secretion.

Baseline IGF-1 for healthy adults typically ranges from 115–300 ng/mL depending on age, with levels declining approximately 14% per decade after age 30. Researchers using the Wolverine stack should expect IGF-1 elevation of 30–50% from baseline within 6–8 weeks if peptides are dosed correctly and are pharmacologically active. An IGF-1 level that remains unchanged after 8 weeks of consistent dosing suggests one of three problems: underdosed or inactive peptides, incorrect reconstitution or storage (peptides degraded before administration), or non-response due to pituitary desensitisation or liver dysfunction.

IGF-1 above 400 ng/mL in adults signals supraphysiological GH exposure. The range associated with acromegaly risk markers like joint pain, carpal tunnel symptoms, and glucose dysregulation. Most research protocols target IGF-1 in the upper-normal reference range (250–300 ng/mL) rather than pushing into supraphysiological territory. IGF-1 binding protein 3 (IGFBP-3) can be added as a secondary marker. It rises alongside IGF-1 and provides additional confirmation of GH axis activation, though it's not required for basic protocol monitoring.

Metabolic Panels and Glucose Regulation

Growth hormone is a counter-regulatory hormone. It opposes insulin signalling and promotes hepatic gluconeogenesis, which is why researchers using the Wolverine stack must monitor fasting glucose, HbA1c, and comprehensive metabolic panel (CMP) markers throughout the protocol. GH-induced insulin resistance is dose-dependent and typically reversible, but it compounds existing metabolic dysfunction in researchers with pre-diabetes or metabolic syndrome.

Fasting glucose should be measured at baseline and every 6–8 weeks during active protocols. Normal fasting glucose is 70–99 mg/dL; pre-diabetic range is 100–125 mg/dL. A fasting glucose increase of 5–10 mg/dL during a Wolverine stack protocol is common and generally benign, reflecting mild GH-induced gluconeogenesis. An increase exceeding 15 mg/dL or any reading above 110 mg/dL warrants dose reduction or protocol cessation, especially if HbA1c begins trending upward.

HbA1c (glycated haemoglobin) reflects average blood glucose over the previous 90 days. Baseline HbA1c establishes metabolic health before starting the stack. Normal is below 5.7%, pre-diabetic range is 5.7–6.4%, and diabetic range is 6.5% or higher. HbA1c rising by 0.2–0.3% during a peptide protocol signals worsening glucose regulation and requires immediate dose adjustment. Researchers with baseline HbA1c above 5.5% should consider skipping growth hormone secretagogues entirely or working with lower doses under closer monitoring.

The comprehensive metabolic panel (CMP) includes electrolytes, kidney function markers (creatinine, BUN), and liver enzymes. Creatinine and BUN typically remain stable on growth hormone protocols unless dehydration or renal stress is present. Sodium, potassium, and chloride should stay within normal ranges. Electrolyte shifts are rare but can occur with significant fluid retention, which some researchers experience on higher doses of GHRP-6 due to ghrelin-mediated appetite and water retention effects.

Lipid Panel and Cardiovascular Markers

Growth hormone exerts complex effects on lipid metabolism. It promotes lipolysis (fat breakdown) while also influencing LDL receptor activity and hepatic lipid synthesis. The net effect varies by dose, duration, and individual metabolic context. Researchers using the Wolverine stack should track a full lipid panel at baseline and 8–12 weeks into the protocol to assess whether favourable or adverse lipid shifts are occurring.

Total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides make up the standard lipid panel. Growth hormone protocols typically reduce triglycerides by 10–20% and may increase HDL slightly. Both favourable changes. LDL cholesterol response is variable: some researchers see modest LDL reduction (5–10%), while others experience LDL increases of similar magnitude. An LDL increase exceeding 15% or any LDL reading above 160 mg/dL (or above 130 mg/dL in researchers with cardiovascular risk factors) warrants protocol adjustment.

Apolipoprotein B (ApoB) is a more precise cardiovascular risk marker than LDL cholesterol. It directly measures the number of atherogenic lipoprotein particles rather than estimating cholesterol content. ApoB below 90 mg/dL is optimal; levels above 120 mg/dL indicate elevated cardiovascular risk regardless of LDL-C. Researchers with baseline ApoB above 100 mg/dL should consider adding this marker to follow-up panels, as GH protocols that lower triglycerides can still worsen particle count in some metabolic contexts.

Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor that growth hormone does not typically alter. Testing Lp(a) at baseline establishes whether this independent risk factor is present. Levels above 50 mg/dL confer significantly elevated cardiovascular risk and may influence the decision to run a growth hormone secretagogue protocol at all, especially in researchers over 40 with other risk factors.

Wolverine Stack Research Bloodwork to Track: Panel Comparison

Biomarker Category	Specific Tests	Baseline Required?	Follow-Up Timing	Why It Matters	Professional Assessment
Growth Hormone Axis	IGF-1, IGFBP-3 (optional)	Yes	6–8 weeks, then every 8–12 weeks	Direct measure of GH secretagogue efficacy; unchanged IGF-1 signals inactive peptides or non-response	IGF-1 is the single most important marker. Without it, you're guessing whether the protocol is working at all
Glucose Regulation	Fasting glucose, HbA1c, fasting insulin (optional)	Yes	Fasting glucose every 6–8 weeks; HbA1c every 12 weeks	GH opposes insulin signalling; dose-dependent glucose elevation signals metabolic stress	Any HbA1c increase ≥0.3% or fasting glucose ≥110 mg/dL requires immediate dose reduction
Metabolic Panel (CMP)	Creatinine, BUN, electrolytes (Na/K/Cl), liver enzymes (AST/ALT)	Yes	Every 8–12 weeks	Kidney function, electrolyte balance, hepatic stress markers; stable CMP confirms protocol safety	Elevated AST/ALT above 1.5× upper limit signals hepatic stress. Rare but serious
Lipid Panel	Total cholesterol, LDL, HDL, triglycerides, ApoB (optional), Lp(a) (baseline only)	Yes	8–12 weeks, then every 12 weeks	GH promotes lipolysis but can increase LDL in some contexts; triglyceride reduction is common	ApoB is the most precise cardiovascular risk marker. LDL-C alone misses particle count
Thyroid Function	TSH, free T3, free T4	Yes	Every 12 weeks if baseline abnormal; otherwise 16–20 weeks	GH can alter T4-to-T3 conversion; low T3 with elevated rT3 signals thyroid suppression	Most researchers skip thyroid panels. Mistake, especially if energy or recovery declines mid-protocol
Prostate Health (males)	PSA (prostate-specific antigen)	Yes if age ≥40	Every 12 weeks	GH does not directly elevate PSA but may accelerate existing prostate tissue growth	Any PSA increase ≥0.5 ng/mL or reading ≥2.5 ng/mL warrants urology referral

What If: Wolverine Stack Research Bloodwork Scenarios

What If IGF-1 Doesn't Increase After 8 Weeks?

Stop the current protocol and reassess peptide source, reconstitution method, and storage conditions. IGF-1 that remains unchanged after 8 weeks of consistent dosing indicates one of three failures: peptides are underdosed or inactive (most common with unverified suppliers), peptides degraded due to improper storage or reconstitution (lyophilised peptides must be stored at −20°C before reconstitution and refrigerated at 2–8°C after mixing with bacteriostatic water), or pituitary non-response (rare, typically due to prior GH axis suppression or pituitary pathology). Switching to a verified peptide source and re-testing IGF-1 at 6 weeks is the standard next step.

What If Fasting Glucose Rises Above 110 mg/dL During the Protocol?

Reduce peptide dose by 30–40% and recheck fasting glucose in 3–4 weeks. Growth hormone-induced insulin resistance is dose-dependent and reversible. Lowering the dose typically brings glucose back into normal range within 2–3 weeks. If fasting glucose remains elevated or HbA1c increases by 0.3% or more, discontinue the protocol entirely. Researchers with baseline HbA1c above 5.5% or fasting glucose above 95 mg/dL should not run growth hormone secretagogue protocols without endocrinology consultation, as they're at significantly higher risk for glucose dysregulation.

What If Liver Enzymes (AST/ALT) Elevate During the Protocol?

Discontinue the protocol immediately and recheck liver enzymes in 2–3 weeks. AST or ALT above 1.5× the upper reference limit (typically >60–75 U/L depending on the lab) signals hepatic stress. Growth hormone secretagogues do not typically cause liver toxicity, so elevated enzymes suggest either peptide contamination, concurrent supplement use (especially oral anabolics or high-dose fat-soluble vitamins), or unrelated liver pathology. If enzymes normalise after stopping the protocol, the peptides were likely the culprit. If they remain elevated, further hepatic workup is required.

What If Lipids Worsen — LDL or ApoB Increases Significantly?

Adjust dose downward or add lipid management strategies before discontinuing the protocol. An LDL increase of 10–15% or ApoB increase above 110 mg/dL during a Wolverine stack protocol is uncommon but documented in some individuals. Growth hormone promotes lipolysis, which should improve lipid profiles, but individual metabolic context. Especially existing insulin resistance or metabolic syndrome. Can cause paradoxical LDL elevation. Reducing peptide dose by 25–30%, increasing aerobic activity, and tightening dietary saturated fat intake typically reverses the trend within 8–10 weeks. If lipids continue worsening or ApoB exceeds 130 mg/dL, discontinue the protocol.

The Honest Truth About Wolverine Stack Bloodwork

Here's the honest answer: most researchers skip bloodwork entirely or run it once at baseline and never follow up. That's not research. That's guessing. The Wolverine stack research bloodwork to track isn't expensive (a full panel including IGF-1, CMP, lipids, HbA1c, and thyroid function costs $150–$250 through direct-to-consumer lab services), and it's the only way to know whether the peptides are real, whether the dose is appropriate, and whether adverse metabolic shifts are occurring before they become irreversible. Running a growth hormone secretagogue protocol without serial bloodwork is like driving blind. You might arrive safely, but you won't know if you're heading off a cliff until it's too late.

IGF-1 is the single biomarker that proves efficacy. If your IGF-1 hasn't moved after 8 weeks, your peptides are either fake, degraded, or dosed incorrectly. And no amount of

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

IGF-1 (insulin-like growth factor 1) is the most direct and reliable biomarker for assessing growth hormone secretagogue efficacy. When GHRP-2, GHRP-6, or ipamorelin stimulates pituitary GH release, the liver synthesises IGF-1 within 4–6 hours. Researchers should expect IGF-1 elevation of 30–50% from baseline within 6–8 weeks if peptides are dosed correctly and pharmacologically active. An IGF-1 level that remains unchanged after 8 weeks signals inactive peptides, incorrect storage, or pituitary non-response — making it the primary pass/fail metric for any growth hormone secretagogue protocol.

Baseline bloodwork before starting the protocol is mandatory, followed by comprehensive follow-up at 6–8 weeks and again at 12 weeks. The 6–8 week panel confirms whether IGF-1 has increased (proving peptide efficacy) and whether glucose, liver enzymes, or lipids have shifted adversely. After the first 12 weeks, follow-up every 8–12 weeks is sufficient for stable protocols. Researchers who skip follow-up bloodwork have no way to detect early metabolic dysfunction, peptide degradation, or dose miscalculation — all of which are common but invisible without serial lab testing.

No — subjective wellness is not a valid substitute for objective biomarker tracking in peptide research. Growth hormone-induced insulin resistance, hepatic stress, and lipid changes develop silently over weeks to months and won’t produce symptoms until dysfunction is advanced. Fasting glucose can rise from 90 mg/dL to 115 mg/dL (pre-diabetic range) without any noticeable change in energy or recovery. Liver enzymes can double without causing fatigue or discomfort. Cardiovascular risk accumulation from adverse lipid shifts is entirely asymptomatic. Running peptides based on how you feel guarantees you’ll miss early warning signs — bloodwork is not optional.

An IGF-1 increase confirms the peptides are working, but a significant fasting glucose increase (≥10 mg/dL or any reading above 105 mg/dL) signals dose-dependent insulin resistance. Growth hormone opposes insulin signalling, and while mild glucose elevation (5–8 mg/dL) is common and generally benign, larger increases indicate the dose is too high for your current metabolic capacity. The correct response is to reduce peptide dose by 30–40% and recheck glucose in 3–4 weeks. If glucose normalises, continue at the lower dose. If it remains elevated or HbA1c increases, discontinue the protocol.

Growth hormone can suppress peripheral conversion of T4 (thyroxine) to T3 (triiodothyronine), the active thyroid hormone responsible for metabolic rate and energy production. Some researchers experience declining free T3 levels with normal or elevated TSH during GH secretagogue protocols, leading to fatigue, reduced recovery, and lower metabolic rate despite rising IGF-1. Testing TSH, free T3, and free T4 at baseline and every 12 weeks allows early detection of thyroid axis suppression. Researchers with pre-existing subclinical hypothyroidism (TSH >2.5 mIU/L) are at higher risk and should monitor thyroid function more closely.

LDL cholesterol measures the amount of cholesterol carried inside LDL particles, while ApoB (apolipoprotein B) measures the number of atherogenic lipoprotein particles themselves. ApoB is a more precise cardiovascular risk marker because particle count matters more than cholesterol content — you can have normal LDL-C with high particle count (high ApoB), which confers elevated cardiovascular risk. Growth hormone protocols can lower triglycerides and raise HDL (favourable) while paradoxically increasing LDL particle number in some individuals. ApoB below 90 mg/dL is optimal; levels above 120 mg/dL indicate elevated risk regardless of LDL-C.

Yes, if you’re over 40 or have any family history of prostate issues. Growth hormone does not directly cause prostate cancer, but it can accelerate the growth of existing prostate tissue, including benign prostatic hyperplasia (BPH) or undetected malignancies. Baseline PSA establishes your starting point, and follow-up every 12 weeks detects any abnormal increases. A PSA increase of 0.5 ng/mL or more, or any reading above 2.5 ng/mL, warrants urology consultation and possible protocol cessation. Skipping PSA monitoring in males over 40 is a significant oversight in long-term peptide research protocols.

Discontinue the protocol immediately and recheck liver enzymes in 2–3 weeks. AST or ALT above 1.5× the upper reference limit signals hepatic stress, which is uncommon with pure growth hormone secretagogues but can occur due to peptide contamination, concurrent supplement use, or unrelated liver pathology. If enzymes normalise after stopping peptides, the protocol was likely the cause. If they remain elevated, further hepatic workup (including imaging and viral hepatitis screening) is required. Growth hormone secretagogues are not inherently hepatotoxic, so elevated liver enzymes always warrant investigation rather than continuation.

A full panel including IGF-1, comprehensive metabolic panel (CMP), lipid panel, HbA1c, thyroid function (TSH, free T3, free T4), and PSA (for males) typically costs $150–$250 through direct-to-consumer lab services like Ulta Lab Tests, Quest Direct, or LabCorp OnDemand. Insurance rarely covers peptide research bloodwork, so out-of-pocket pricing applies. Baseline plus two follow-up panels over 12 weeks totals $450–$750 — less than the cost of three months of research-grade peptides. The cost of bloodwork is negligible compared to the cost of undetected metabolic dysfunction or wasted money on inactive peptides.

At-home finger-prick tests are acceptable for basic markers like fasting glucose and total cholesterol, but they’re insufficient for comprehensive Wolverine stack monitoring. IGF-1, HbA1c, liver enzymes (AST/ALT), and full lipid panels (including ApoB) require venous blood samples with laboratory analysis for accurate, reproducible results. Finger-prick tests often have wider error margins and lower precision, especially for low-volume analytes like IGF-1. If venous draws are inaccessible, at-home HbA1c and lipid testing can supplement — but not replace — venous bloodwork for IGF-1 and metabolic panels.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA